Brief: Pacira Biosciences Inc - Receives Paragraph Iv Notice From Qilu Pharmaceutical
27/10/2025 13:29
Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES INC - RECEIVES PARAGRAPH IV NOTICE FROM QILU PHARMACEUTICAL PACIRA BIOSCIENCES INC - QILU ALLEGES 18 EXPAREL PATENTS INVALID OR UNENFORCEABLE Source text: ID:nGNX261HCp Further company coverage: PCRX.O
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal